ClinicalTrials.gg
CompletedNCT04469920Updated Sep 20, 2024

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

A Phase 1 interventional study of Saroglitazar Magnesium 2 mg and Saroglitazar Magnesium 4 mg in Hepatic Impairment, sponsored by Zydus Therapeutics Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This will be a Phase 1, Open-label Study of Participants with Hepatic Impairment, Cholestatic Liver Disease, and NASH with Advanced Fibrosis and Normal Hepatic Function

Read the detailed description

Male and female participants 18-80 years of age (inclusive) with normal hepatic function or hepatic impairment/disease who meet all of the inclusion and none of the exclusion criteria. Subjects with hepatic impairment will be enrolled based upon the Child-Pugh-Turcotte (CPT) classification system for mild hepatic impairment (Group 1 CPT Class A without PHT; Group 2 CPT Class A with PHT), moderate hepatic impairment (Group 3 Decompensated CPT Class B), or severe hepatic impairment (Group 4 Decompensated CPT Class C). Group 5 will include subjects with cholestatic liver disease and Group 6 will include subjects with non-cirrhotic advanced fibrosis secondary to NASH (non-alcoholic steatohepatitis). The control group (Group 7) will consist of demographic matched subjects with normal hepatic function.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Zydus Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 5 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to comprehend and willingness to sign a written for the study.
  2. Male or female aged 18 to 80 years (inclusive) at the time of signing the ICF.
  3. within the range 18.0 to 48.0 kg/m2 (inclusive) at screening.
  4. Females must be non-pregnant, non-lactating and of non- or using highly efficient for the full duration of the study.
  5. Females of child-bearing potential and Males must agree to use contraception for the full duration of the study.
  6. Ability to swallow and retain oral medication.
  7. Groups 1 through 6 subjects may have medical findings consistent with their degree of hepatic dysfunction, as determined by medical history, physical examination, vital signs, ECGs, and clinical laboratory examinations at screening and check-in. Participants with abnormal findings considered not by the Investigator are eligible.
  8. Participants with hepatic impairment in Groups 1-4 will be classified at screening based on CPT score. If the hepatic impairment classification for the subject is not the same at screening and day -1, enrolment of the subject into a hepatic category group will be at the discretion of the hepatology Investigator.
  9. Laboratory test values for Groups 1-4 hepatic impairment subjects must be clinically acceptable to the Investigator and meet all of the following parameters at Screening:

    1. /AST value ≤ 10 × (ULN)
    2. (ANC) ≥ 750/mm3
    3. ≥ 25,000/mm3
    4. ≥ 8 g/dL
    5. α-fetoprotein \< 50 ng/mL or 50-80 ng/mL with concurrent negative imaging study (US, CT, MRI)
  10. Group 2 must have evidence of PHT as manifested by one of the following:

    1. presence of hepatic encephalopathy or ascites (on exam or imaging or medication to control these symptoms),
    2. historical or current presence of varices by imaging or endoscopy,
    3. historical or current presence of splenomegaly by imaging or physical exam,
    4. previous Hepatic Venous Pressure Gradient Measurement (HVPG) >10 mmHg,
    5. platelet count \<150,000/mm3 (or /uL), or
    6. Fibroscan® at screening >20 kPa.
  11. Documented history of cholestatic liver disease (i.e. primary biliary cholangitis, primary sclerosing cholangitis) OR alkaline phosphatase at screening of >1.25 x ULN with AST/ALT \<1.2 x ULN OR Historical presence of AMA (anti-mitochondrial antibody) >1:40 and elevated alkaline phosphatase > ULN at screening
  12. Clinical diagnosis of NASH and the following criteria:

    a. Screening Fibroscan® with liver stiffness > 8.5 kPa AND CAP >280 dB AND At least two criteria for metabolic syndrome modified from the NCEP

    ATP III Guidelines, at screening:

    i. Fasting glucose >100 mg/dL or receiving drug treatment for elevated glucose, ii. Fasting HDL cholesterol \<40 mg/dL in men and \<50 mg/dL in women or receiving drug treatment for low HDL cholesterol, iii. Fasting triglycerides > 150 mg/dL or receiving drug treatment for hypertriglyceridemia, iv. Waist circumference >102 cm for men or >88 cm for women or BMI >30 kg/m2, v. Systolic blood pressure >130 mmHg or diastolic blood pressure >85 mmHg or receiving drug treatment for hypertension

    OR:

    b. A historical liver within 6 months of screening consistent with NASH with stage 3 fibrosis and no documented weight loss >10% since date of liver biopsy

  13. Subjects with normal hepatic function must match in age (± 10 years), gender, and weight (± 10 kg) with hepatic disease participants in the Groups 1-6.
  14. Subjects should be in good health as determined by no clinically significant findings in the medical history, physical examination, vital signs, 12-lead (ECGs), or laboratory examinations at Screening or Check-in.
  15. Laboratory test values within normal limits or considered not clinically significant by the Investigator for subjects with normal hepatic function including ALT/AST \< 1.2 × ULN at screening.

Exclusion criteria

Exclusion Criteria:

  1. Any significant, unstable medical condition or other instability that would prevent the subject from participating in the study as determined by the Investigator or designee.
  2. History of of any type in the last 3 years of screening, with the exception of the following: in situ cervical or breast cancer or surgically excised non-melanoma skin cancers (i.e. basal cell or squamous cell carcinoma).
  3. History of stomach or intestinal surgery or resection within the six months prior to screening that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed).
  4. History of any significant drug allergy (such as anaphylaxis) deemed by the Investigator.
  5. Any major surgery within 3 months of screening.
  6. Donation of blood or blood products within 3 months prior to screening.
  7. Current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment or symptoms of active infectious disease within the two weeks prior to screening.
  8. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, within 21 days prior to screening, unless deemed acceptable by the Investigator.
  9. Receiving or has received any drug within the 30 days or 5 halflives (whichever is longer), before receiving Saroglitazar Magnesium.
  10. Estimated (eGFR) \< 60 mL/min/1.73m2 by modification of diet in renal disease (MDRD) formula at screening.
  11. Positive alcohol breath test at the time of check-in or those subjects who have current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance or subject safety.
  12. Positive test for drugs of abuse at screening or admission.
  13. Any subject with poor peripheral venous access
  14. Receipt of blood products within 1 month prior to check in.
  15. (HIV) type 1 antibody positive at screening for all groups.
  16. Subjects who have had a change in hepatic disease status within 30 days of screening, as documented by the participant's medical history and deemed clinically significant by the Investigator.
  17. > 500 msec, confirmed by repeat measurement OR presence of second- or third-degree atrioventricular (AV) block.
  18. Subjects having -

    1. History of gastrointestinal bleeding within 1 month prior to screening.
    2. Current functioning organ transplant.
    3. Evidence of severe ascites requiring frequent paracentesis in the opinion of investigator.
  19. Subjects having a history of any of the following: hepatic encephalopathy, ascites, history or current presence of varices by imaging or endoscopy, history or current presence of splenomegaly by imaging or physical exam, previous HVPG >10, count \<150,000 (or /uL) at screening, or Fibroscan® at screening >20 kPa.
  20. QT interval corrected for heart rate using Fridericia's method (QTcF) > 450 msec, confirmed by repeat measurement OR presence of second- or third-degree AV block.
  21. virus surface antigen (HBsAg) positive, virus antibody (HCV-Ab) positive.
  22. Subjects who use or intend to use any over the counter (vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) or prescription medications within 30 days or 5 half-lives (whichever is longer) prior to enrolment, with the exception of hormone replacement therapy and therapies for hepatic disease and treatments of associated disorders that have been stable for at least 30 days prior to screening and until Day 1, unless deemed acceptable by the Investigator (or designee).
  23. Other known cause of liver disease such as NASH, Alcoholic Steatohepatitis (ASH), hepatitis, or acute or chronic viral hepatitis as determined by the Investigator and subject's medical records
  24. Evidence of liver decompensation such as ascites, hepatic encephalopathy or prior history of variceal bleed.
  25. No other known cause of liver disease such as Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Alcoholic Steatohepatitis (ASH), autoimmune hepatitis, or acute or chronic viral hepatitis as determined by the Investigator and subject's medical records
  26. Platelet count \<150,000 (or /uL)
  27. Subjects who have taken any prescription medications or over-the-counter medications, including herbal products, within 14 days prior to start of study drug dosing, with the exception of vitamins, acetaminophen, hormonal medications and/or any other over-the-counter product approved by the Investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Group 1- mild hepatic impairment without evidence of PHT

    Subject with mild hepatic impairment without evidence of portal hypertension (PHT) based on Class A CPT score 5-6 points

    Drug: Saroglitazar Magnesium 4 mg

  • Experimental
    Group 2- mild hepatic impairment with evidence of PHT

    Subjects with mild hepatic impairment with evidence of portal hypertension based on Class A CPT score 5-6 points

    Drug: Saroglitazar Magnesium 4 mg

  • Experimental
    Group 3-moderate hepatic impairment

    Subjects with moderate hepatic impairment based on Class B CPT score 7-9 points

    Drug: Saroglitazar Magnesium 4 mg

  • Experimental
    Group 4- severe hepatic impairment

    Subjects with severe hepatic impairment based on Class C CPT score 10-14 points)

    Drug: Saroglitazar Magnesium 4 mg

  • Experimental
    Group 5-cholestatic liver disease

    Subjects with cholestatic liver disease

    Drug: Saroglitazar Magnesium 2 mg · Drug: Saroglitazar Magnesium 4 mg

  • Experimental
    Group 6-Non-cirrhotic Advanced Fibrosis secondary to NASH

    Subjects with Non-cirrhotic Advanced Fibrosis secondary to NASH

    Drug: Saroglitazar Magnesium 2 mg · Drug: Saroglitazar Magnesium 4 mg

  • Experimental
    Group 7- normal hepatic function

    Subjects with normal hepatic function

    Drug: Saroglitazar Magnesium 2 mg · Drug: Saroglitazar Magnesium 4 mg

Interventions

06

What researchers measure

Primary outcomes

  1. AUC from time zero to infinity (AUC0-∞)

    The area under the plasma concentration versus time curve from zero to infinity will be calculated by adding Ct/Kel to AUCt, where Ct is the last quantifiable concentration and Kel is the elimination rate constant.

    Time frame: Before dosing on Day 1 through Day 7

  2. AUC from time zero to the last quantifiable concentration (AUC0-t)

    The area under the plasma concentration versus time curve will be calculated using the linear trapezoidal rule from the zero time point to the last quantifiable concentration.

    Time frame: Before dosing on Day 1 through Day 7

  3. Cmax

    Maximum measured plasma concentration over the time span specified.

    Time frame: Before dosing on Day 1 through Day 7

  4. Tmax

    Time of the maximum measured plasma concentration.

    Time frame: Before dosing on Day 1 through Day 7

  5. t1/2

    The half-life will be calculated by the equation tHalf = 0.693/ Kel. Kel (The terminal elimination rate constant) will be obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the natural log of the concentration versus time plot for these points

    Time frame: Before dosing on Day 1 through Day 7

  6. CL/F

    Clearance

    Time frame: Before dosing on Day 1 through Day 7

  7. Vz/F

    Volume of distribution

    Time frame: Before dosing on Day 1 through Day 7

Secondary outcomes

  1. Urine Pharmacokinetic: Ae

    Amount of drug excreted during each collection interval

    Time frame: Before dosing on Day 1 through Day 5

  2. Incidence of AEs

    Incidence and severity of AEs as a measure of safety and tolerability will be measured and reported.

    Time frame: Before dosing on Day 1 through Day 12

  3. Unbound Fraction

    Unbound fraction in plasma of Saroglitazar

    Time frame: Day 1

  4. Unbound concentration

    Unbound concentration in plasma of Saroglitazar

    Time frame: Day 1

07

Study locations

2 sites
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • American Research Corporation at Texas Liver Institute
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Mar 2022, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2020
First posted
Jul 14, 2020
StartActual
Jul 16, 2020
Primary completionActual
Mar 21, 2022
CompletionActual
Mar 21, 2022
Last update
Sep 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04469920
Responsible party
Sponsor
First posted
Jul 14, 2020
Start date
Jul 16, 2020
Primary completion
Mar 21, 2022
Completion
Mar 21, 2022
Last update
Sep 20, 2024

Study contacts

Deven Parmar, MD
study director · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion